Technology
Health
Biotechnology

La Jolla Pharmaceutical

$6.76
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.33 (-4.65%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell LJPC and other stocks, options, ETFs, and crypto commission-free!

About

La Jolla Pharmaceutical Co. operates as a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. Its products includes LJPC-501, LJPC-401 and LJPC-0118. Read More LJPC-501 is the proprietary formulation for angiotensin II. The LJPC-401 is the formulation of hepcidin, which is an endogenous peptide hormone and LJPC-0118 is La Jolla's investigational product for the treatment of severe malaria. The company was founded in 1989 and is headquartered in San Diego, CA.

Employees
169
Headquarters
San Diego, California
Founded
1989
Market Cap
177.51M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
584.49K
High Today
$7.13
Low Today
$6.74
Open Price
$7.07
Volume
361.33K
52 Week High
$38.39
52 Week Low
$5.01

Collections

Technology
Health
Biotechnology
Pharmaceutical
Biopharmaceutical
US
North America

News

Simply Wall StMar 11

La Jolla Pharmaceutical Company (NASDAQ:LJPC): Immense Growth Potential?

The latest earnings release La Jolla Pharmaceutical Company’s (NASDAQ:LJPC) announced in December 2018 suggested that losses became smaller relative to the prior year’s level as a result of recent tailwinds Today I want to provide a brief commentary on how market analysts view La Jolla Pharmaceutical’s earnings growth trajectory over the next couple of years and whether the future looks brighter.

213
Yahoo FinanceMar 6

Do Options Traders Know Something About La Jolla Pharmaceutical (LJPC) Stock We Don't?

Investors in La Jolla Pharmaceutical Company LJPC need to pay close attention to the stock based on moves in the options market lately.

236
Seeking AlphaMar 4

La Jolla Pharmaceutical Company (LJPC) CEO George Tidmarsh on Q4 2018 Results - Earnings Call Transcript

La Jolla Pharmaceutical Company (NASDAQ:LJPC) Q4 2018 Results Conference Call March 4, 2019 4:30 PM ET Company Participants Sandra Vedrick - Director of Investor Relations and Human Resources George Tidmarsh - President and Chief Executive Officer Dennis Mulroy - Chief Financial Officer Jennifer Carver - Chief Operating Officer Conference Call Participants Joon Lee - SunTrust Robinson Phil Nadeau - Cowen and Company Kyung Yang - Jefferies Ed White - H.C. Wainwright Tessa Romero - JPMorgan Operat...

170

Earnings

-$2.22
-$1.88
-$1.53
-$1.19
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Expected May 9, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.